Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-12-08

FDA Approved: LEVEMIR — Supplemental Application (Novo Nordisk)

View source ↗

Summary

The FDA approved a supplemental application for LEVEMIR (insulin detemir) from Novo Nordisk, resulting in labeling changes related to the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Levemir (insulin detemir)

Snippet

SUPPL AP for LEVEMIR (INSULIN DETEMIR)